Mechanisms underlying the thymic involution induced by a murine mammary adenocarcinoma (Meeting abstract).

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Mechanisms underlying the thymic involution induced by a murine mammary adenocarcinoma (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 38:A2326 1997. Unique Identifier : AIDSLINE ICDB/98639326
Sun Q; Adkins B; Lobo D; Zacharievich N; Charyulu V; Lopez DM; Department of Microbiology and Immunology, University of Miami; School of Medicine, Miami, FL 33136

Abstract: A profound thymic atrophy has been observed in mice bearing large adenocarcinomas of the mammary gland. Although there is no decrease in the overall percentages of Thy-1+ cells in tumor bearers, the majority of the remaining cells are of a Thy-1 low phenotype. There was a dramatic decrease in the percentage of double positive (CD4+, CD8+) cells, and an increase in single-positive thymocytes and double negative (CD4-, CD8-) thymocytes in tumor-bearing mice indicating that proportionally less immature thymocytes are present in the atrophic thymuses of mammary tumor bearers. The levels of apoptosis were determined by three methods: formation of DNA ladder on gel electrophoresis, presence of sub G1 peak by FACS analysis, and Tunel assays. No differences in apoptosis were noted between the two types of mice, either in their thymuses or in peripheral T cells. Instead, further phenotypical characterizations gave evidence consistent with a partial arrest at the CD44+ CD25+ double negative stage or an earlier stage of thymic differentiation in tumor bearing mice, possibly brought about by tumor derived factors.

Keywords: Animal Apoptosis Atrophy *Leukocyte Count Mammary Neoplasms, Experimental/*IMMUNOLOGY/*PATHOLOGY Mice Phenotype T-Lymphocytes/*PATHOLOGY Th1 Cells ABSTRACT
980228
M9820754

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .